Breaking Down Zhejiang Jingxin Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Discover how Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ), founded in 1990, has built a powerhouse around a mission of 'careful protection of health' and a vision to lead China's neuropsychiatry, cardiovascular and cerebrovascular fields while becoming a 'first-class enterprise' globally; with a registered capital of 860 million yuan, total assets of 8.479 billion yuan, a workforce of over 3,900 employees including more than 230 doctoral and master's talents, two headquarters (Xinchang and Hangzhou), seven production sites across China, a research institute in Shanghai's Zhangjiang Hi‑Tech Park and international collaborations in the USA, Denmark, Israel and Korea, Jingxin pairs strategic focus on chemical preparations, traditional Chinese medicines, biological agents and medical devices with core values of pragmatic, innovative, inclusive and win‑win, reinforced by certifications such as the new GMP and FDA on‑site approval and repeated inclusion among the 'Top 100 Chinese Pharmaceutical Industry Brands'-read on to see how these concrete strengths power their mission, vision and value-driven growth.

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) Intro

• Registered capital: ¥860 million
• Total assets: ¥8.479 billion
• Employees: >3,900, including >230 with doctoral or master's degrees
• Headquarters: Xinchang and Hangzhou
• Production sites: 7 (Xinchang, Shangyu, Shandong, Bayannaoer, Shenzhen, Shenyang, plus regional facilities)
• R&D presence: Research institutes in Shanghai Zhangjiang Hi‑Tech Park; joint ventures/collaborative labs in USA, Denmark, Israel, Korea
• Industry recognition: Regularly listed among 'Top 100 Chinese Pharmaceutical Industry Brands' and 'Top 100 Chinese Pharmaceutical Enterprises'

Mission Statement

• Develop safe, effective, and affordable therapeutics that improve neurological and cardiovascular patient outcomes.
• Integrate innovative R&D with scalable manufacturing to deliver high-quality pharmaceuticals globally.
• Commit to scientific excellence, regulatory compliance, and sustainable growth that benefits patients, employees, and shareholders.

Vision

• Be a leading global specialty pharmaceutical company in neuropsychiatry and cardiovascular health.
• Advance translational science from Zhangjiang and international collaborations into market-ready therapies.
• Expand market presence through diversified product lines across chemical, biological, and TCM sectors while achieving long-term, asset-efficient growth.

Core Values

• Patient-first: Prioritize safety, efficacy, and accessibility in all products and decisions.
• Innovation: Invest in R&D talent (230+ advanced degree holders) and global partnerships to accelerate novel therapies.
• Quality & Compliance: Maintain stringent manufacturing standards across seven production sites to ensure consistent product integrity.
• Collaboration: Leverage joint ventures and labs in the USA, Denmark, Israel, and Korea to source global expertise and technologies.
• Sustainability & Responsibility: Drive responsible growth reflected in stable asset base (¥8.479B) and diversified operations.
• Employee Development: Foster a skilled workforce through recruitment, training, and retention to support R&D and production excellence.

For investor-focused context and a deeper look at shareholder activity, see: Exploring Zhejiang Jingxin Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) - Overview

• Mission statement: careful protection of health - delivering safe, effective therapies with a quality-first mindset captured by the motto 'Jingxin drug, meticulously made.'
• Strategic focus: lead therapeutic positions in neuropsychiatric and cardiovascular fields; strengthen core pharmaceuticals and develop medical devices as complementary growth engines.
• Core values: pragmatic, innovative, inclusive, and win-win - applied across R&D, manufacturing, commercialization, and partnerships.
• Quality and compliance: full commitment to global quality standards - passed the newer-version GMP certification and completed an on-site FDA inspection and certification for key facilities.

• Vision: establish Zhejiang Jingxin as a leading, trusted supplier of neuropsychiatric and cardiovascular medicines domestically and a growing exporter internationally, leveraging quality manufacturing and targeted innovation.
• Quality philosophy: 'Jingxin drug, meticulously made' - operationalized through standardized quality systems, continuous process improvement, and external regulatory approvals.
• Business guideline implementation:
• • Strengthening the main pharmaceutical business: prioritizing pipeline optimization, therapeutic franchise building, and scale-up of high-margin finished dosage forms.
  • Developing medical devices: selective expansion into device components and combination products aligned with core therapy areas to create integrated care solutions.

• Operational and financial highlights demonstrating mission-driven execution:
• • Regulatory milestones: successful audits and certifications (domestic new-version GMP; FDA on-site inspection) enabling broader export and tender participation.
  • Commercial scale: multi-drug portfolios in neuropsychiatry and cardiovascular categories contributing significant prescription share in targeted provincial markets and growing national presence.
  • R&D pipeline: ongoing clinical and registration projects focused on CNS and cardiovascular indications, supported by steady R&D spend (~5-8% of revenues) to fuel incremental innovation.

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) - Mission Statement

• Core therapeutic focus: leadership in mental health, cardiovascular, and cerebrovascular treatment areas.
• Mission emphasis: "careful protection of health" - prioritizing patient safety, product quality, and population-level impact.
• Global ambition: evolve into a first-class enterprise in global pharmaceutical and healthcare markets through international competitiveness.
• Innovation commitment: continuous pursuit of sustainable innovation - R&D-driven pipeline expansion and process improvements.
• Values-driven operations: excellence in quality, collaborative partnerships, and long-term sustainability.

• Target therapeutic burden: cardiovascular disease is the leading cause of death in China, accounting for roughly 40% of total mortality - underscoring the scale of need Jingxin addresses.
• Stroke and cerebrovascular demand: China records on the order of ~3 million new strokes annually, highlighting the clinical and market imperative for effective cerebrovascular medicines and post-stroke care solutions.
• Mental health prevalence: demographic and epidemiological trends show substantial unmet needs in mental health services and pharmacotherapies across urban and rural China, motivating Jingxin's strategic emphasis.
• R&D and sustainability KPIs: Jingxin's vision ties innovation investment to long-term competitiveness - targeting sustained year-on-year improvement in pipeline output, regulatory approvals, and manufacturing efficiencies.
• Partnership orientation: the company prioritizes alliances with hospitals, research institutes, and global pharma partners to accelerate clinical development, market access, and export growth.

• Public-health alignment: prioritizing therapeutic areas that correspond to major disease burdens (cardiovascular/cerebrovascular and mental health) ensures Jingxin's R&D and commercialization efforts address high-impact clinical needs.
• Scalability: by focusing on hospital formulary penetration and export markets, Jingxin aims to translate domestic clinical relevance into international market share.
• Quality and compliance: "careful protection of health" drives continuous improvement in manufacturing quality, pharmacovigilance, and regulatory compliance to support a first-class global standing.

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) - Vision Statement

• Pragmatic: prioritize practical, scalable solutions across R&D, manufacturing, and supply chain to ensure reliable product availability.
• Innovative: invest in new technologies, sterile processing, and synthetic routes to broaden therapeutic coverage and enhance product quality.
• Inclusive: build collaborative relationships with customers, regulators, and suppliers; foster an internal culture that values diverse expertise and cross-functional teamwork.
• Win-win: pursue partnerships and commercial models that create shared value for patients, healthcare providers, and shareholders.

• Careful protection of health - safety and compliance are non-negotiable across all facilities and product lines.
• Professional, collaborative, innovative, and sharing - expertise-driven teams that emphasize collaboration and knowledge transfer.
• Integrity, struggle, open, learning, responsible, and win-win - ethical conduct, perseverance, openness to change, continuous learning, accountability, and mutually beneficial outcomes.
• Coordinated development and common growth; integrity, pragmatism, and service first; challenge oneself and strive for first place - guiding slogans that translate into KPI-driven performance and continuous improvement.

• Scale sterile and high-purity API capacity to meet growing domestic and export demand.
• Accelerate R&D modularization and platform chemistry to shorten development cycles and lower costs.
• Deepen regulatory alignment (EU/US/ICH standards) to expand global market access.
• Strengthen ESG governance: environmental controls for chemical manufacturing waste, workplace safety, and community health programs.